Fidelity International’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Fidelity International’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,252,000	Closed	-$133M	–	997
2024 Q2	$133M	Buy	3,252,000 +3,000	+0.1%	+$125K	0.13%	186
2024 Q1	$137M	Buy	3,249,000 +483,000	+17%	+$20.3M	0.14%	178
2023 Q4	$117M	Buy	+2,766,000	New	+$79.5M	0.12%	208

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Fidelity International's CERE Position: Q3 2024 in Review

Fidelity International sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 3,252,000 shares — an estimated $133M sold.

Fidelity International first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $137M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Fidelity International reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Fidelity International sold 3,252,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $133M.
Fidelity International first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
Fidelity International's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $137M in Q1 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Fidelity International's 13F filing for Q3 2024, filed 13 Nov 2024.